Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 8/20 | 1.00 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL18378 | 0.81 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29362587 | 0.81 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.80 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.80 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3771017 | 0.80 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115054 | 0.80 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115050 | 0.80 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2324758 | 0.78 | FDPS (0.81) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2324063 | 0.78 | FDPS (0.81) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.78 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683668-A1 | COMPOSITIONS AND METHODS FOR TREATING TENDON AND BONE INJURIES | The United States Government as Represented by The Department of Veterans Affairs (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2024233344-A1 | COMPOSITIONS AND METHODS FOR TREATING TENDON AND BONE INJURIES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-11-14 | — | — | WO | claimed |
| CN-118121702-A | Specific inhibitor of targeted GGTase II and application thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2024-06-04 | — | — | CN | claimed |
| CN-115808525-A | Application of RabGGTase in diagnosis and treatment of amyotrophic lateral sclerosis | 河北医科大学第二医院 | 2023-03-17 | — | — | CN | claimed |
| US-11400104-B2 | Skeletal removal of bisphosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-02 | — | — | US | claimed |
| CN-109219438-B | Bone removal of bisphosphonates | 加州大学董事会 | 2022-04-22 | — | — | CN | claimed |
| US-20210121485-A1 | Skeletal Removal of Bisphosphonates | UNIV CALIFORNIA (US) | 2021-04-29 | — | — | US | claimed |
| EP-4683668-A1 | COMPOSITIONS AND METHODS FOR TREATING TENDON AND BONE INJURIES | The United States Government as Represented by The Department of Veterans Affairs (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024233344-A1 | COMPOSITIONS AND METHODS FOR TREATING TENDON AND BONE INJURIES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118453584-A | Application of lipophilic statin in preparation of medicines for treating autoimmune diseases related to antibody secreting cells | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2024-08-09 | — | — | CN | disclosed |
| CN-118121702-A | Specific inhibitor of targeted GGTase II and application thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2024-06-04 | — | — | CN | disclosed |
| CN-115808525-A | Application of RabGGTase in diagnosis and treatment of amyotrophic lateral sclerosis | 河北医科大学第二医院 | 2023-03-17 | — | — | CN | disclosed |
| CN-115808525-A | Application of RabGGTase in diagnosis and treatment of amyotrophic lateral sclerosis | 河北医科大学第二医院 | 2023-03-17 | — | — | CN | disclosed |
| EP-0788362-B1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMA (US) | 2001-07-25 | — | — | EP | disclosed |
| CN-1048017-C | Phosphonocarboxylate compounds and pharmaceutical compositions containing the same | PROCTER & GAMBLE PHARMA (US) | 2000-01-05 | — | — | CN | disclosed |
| CN-1224018-A | Phosphonic carboxylate compounds, pharmaceutical compositions contg. same | PROCTER & GAMBLE PHARMA (US) | 1999-07-28 | — | — | CN | disclosed |
| US-5760021-A | TREATING OR PREVENTING METABOLIC BONE DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0788362-A1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| CN-1089613-A | Phosphonocarboxylate compounds and pharmaceutical compositions containing the same | PROCTER & GAMBLE PHARMA (US) | 1994-07-20 | — | — | CN | disclosed |
| WO-1993024131-A1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121485-A1 | Skeletal Removal of Bisphosphonates | SOST, ACP3, PTH1R | FDPS 1272/4885BTN3A1 2262/4885PDE3A 1115/4885 |
| US-11400104-B2 | Skeletal removal of bisphosphonates | SOST, ACP3, PTH1R | FDPS 1272/4885BTN3A1 2262/4885PDE3A 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.